What is cash runway?

Cash runway is how long a company's money lasts at its current rate of spending. In startup finance that is a division: cash divided by monthly burn. In a clinical-stage biotech's press release it is not a division at all. When a company says it has "cash runway into the fourth quarter of 2028," it is telling you the date its own management currently expects the money to run out — under a spending plan it has not published, excluding cash it thinks it might receive, and with no obligation to tell you when the estimate changes. It is a forecast about the company's intentions, not a measurement of its bank balance.

That distinction is the whole thing, and it is easy to miss because the phrase is borrowed from somewhere else. The startup-finance version is a number you work out yourself and check every month, and most of what a search returns is written for the finance team doing that division. The biotech version is guidance. And the two answers can be a year apart.

Why the arithmetic doesn't match the number they print

Quantum-Si reported its second quarter on 13 August 2026. The headline said the company was updating the commercial launch of its Proteus instrument to Q2 2027, with cost-reduction actions expected to extend cash runway into Q4 2028. Two facts in one sentence, and they are related in a way worth being explicit about.

The same release gives you the inputs. Cash, cash equivalents and marketable securities were $169.9 million as of 30 June 2026, and total operating expenses for the quarter were $25.8 million. Divide, and you get roughly six and a half quarters — money into early 2028. The guidance says Q4 2028, which is ten quarters out. The gap is about a third of the current quarterly spend.

The release explains the gap, in the bullet directly above the runway line: a reduction in force of approximately 20% of the company's workforce, to align resources and spending with the updated Proteus launch timeline. The company says plainly that the new date rests on the updated operating plan, including the announced workforce reduction and other cost-management actions.

So the runway got longer because the plan got smaller and slower. That is a legitimate thing for a company to do, and it is disclosed in full. It is also the opposite of what "extended cash runway" sounds like on first read.

One limit on the arithmetic above, because it cuts against the point: operating expenses are not cash burn. Non-cash items such as stock-based compensation sit inside that $25.8 million, so the division overstates the rate at which money actually leaves. It is a rough check on the guidance, not a competing forecast. The reason to run it anyway is that when the two disagree by three quarters, something in the plan has changed, and the release usually says what.

What the number leaves out

Runway guidance is bounded by a paragraph most readers skip. REGENXBIO's second-quarter release, on 6 August 2026, states it directly: the guidance is based on current operational plans and excludes material payments that may be received from partners or licensees on development or regulatory milestones, or on approval or commercialization, and excludes any additional potential dilutive or non-dilutive funding.

Read that carefully, because the exclusions run in the company's favour. Everything left out is money that might arrive. A milestone payment, a licensing deal, a share sale — none of it is in the date, so the date is close to a floor under the current plan rather than a central estimate.

The same release shows what happens when the excluded money shows up. REGENXBIO said over $200 million in new capital in July 2026 extends cash runway into Q4 2027, made up of a $100 million milestone payment from AbbVie for dosing the first patient in the Phase IIb/III NAAVIGATE study, and approximately $108 million in net proceeds from an underwritten public offering.

Which breaks the rule the exclusion language seems to teach. It is tempting to read runway as "the date by which they must raise." Companies raise long before that date, usually into good news rather than against a deadline — a pattern worth understanding on its own, and one we have written about separately. Runway tells you when the money runs out if nothing else happens. Something else almost always happens.

The version of the sentence that is actually useful

The best runway disclosures are not measured in calendar quarters at all. They are measured against the next event that changes the company's value.

Coya Therapeutics reported cash and cash equivalents of $43.2 million as of 30 June 2026, sufficient to fund operations, as currently planned, past the Phase 2 ALSTARS topline data readout and into the second half of 2027. The company had said the same thing about the same endpoint nine months earlier, when its chief executive described a financing as extending runway into 2H 2027 and past the ALSTARS topline readout.

The endpoint is pinned to the readout, not to the balance. That framing tells a reader the thing they actually want to know: whether the company can reach the moment that decides its future without selling shares first. A bare date cannot answer that, because you would have to know when the readout is due to make any use of it.

What the sentence is, legally

Two rules define what you are reading, and both are short enough to quote.

A runway statement is a forward-looking statement. Federal law gives the company a safe harbour for it: a forward-looking statement is not actionable in a private suit if it is "identified as a forward-looking statement, and is accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially". That is why every release carries the disclaimer block at the bottom. The block is not decoration; it is the condition on which the projection is protected. A runway date can be wrong, and usually nothing follows from it being wrong.

The more detailed account is in the quarterly filing, not the release, and the rule that governs it comes with a clock. Management's discussion and analysis must analyse the company's ability to generate and obtain cash "in the short-term (i.e., the next 12 months from the most recent fiscal period end required to be presented) and separately in the long-term", and must "identify any known trends or any known demands, commitments, events or uncertainties" that are reasonably likely to move liquidity materially.

Twelve months is the horizon the regulation cares about. So a runway that sits comfortably beyond a year and a runway that sits just inside one are governed by different amounts of required explanation, and the filing is where the explanation is.

What to check when you see the phrase

• What plan is it based on? If the date moved, find out whether cash arrived or spending was cut. The release almost always says, in the bullet above or below.
• What does it exclude? Milestones, partnerships and future raises are usually carved out. Those exclusions make the date conservative, not optimistic.
• Does it clear the next catalyst? A date without a readout attached is much less informative than the company saying it reaches the readout.
• Does the division roughly agree? Cash over quarterly spend is crude, but a large gap between your number and theirs is a question worth answering before you own the stock.
• What does the 10-Q say? The liquidity section carries the reasoning the press release compresses into one clause.

None of this tells you whether a company will succeed. It tells you how much time it has bought itself and what it had to give up to buy it, which is a different and more answerable question.

This is analysis, not investment advice.